UCLA researchers have developed novel PAC1 receptor agonists (MAXCAPs) that specifically bind and activate PAC1 receptors to induce satiety and treat multiple metabolic diseases.
UCLA researchers discovered compounds that specifically binding and activating pituitary adenylate cyclase receptor 1 (PAC1) significantly increase satiety and lean mass while suppressing appetite, fat accumulation and blood glucose levels. One of the endogenous ligands for PAC1 is pituitary adenylate cyclase activating polypeptide (PACAP) which has 68% sequence homology to its closest hormone relative vasoactive intestinal peptide (VIP) and binds with 1000-fold greater affinity to the PAC1 receptor than to the VIP specific receptors VPAC1 and VPAC2 that have opposite metabolic effects relative to PAC1.
PACAP itself is not metabolically stable, as it is rapidly proteolyzed, so the UCLA team is developing new proteolytically stable compounds (MAXCAP’s) that specifically activate PAC1. The lead compound is a 28 residue peptide that has been validated in pre-clinical animal models to demonstrate that it:
MAXCAPs have been shown to reduce appetite and food intake, to switch metabolism to a fat burning (ketosis state), and to treat obesity, insulin resistance, pre-diabetic syndrome and type 2 diabetes. They also have activity in treating hepatosteatosis (fatty liver disease). Currently there are no effective methods or pharmacological targets to treat this disorder.
The inventors have synthesized MAXCAP compounds and tested them extensively in vivo and in vitro using cell culture and mouse models.
PAC1 receptor, MAXCAP, satiety, appetite, metabolic syndrome, insulin resistance, prediabetic syndrome, diabetes, obesity, chronic inflammation, fatty liver disease, NASH, NAFLD